A number of effective therapies for the treatment of osteoporosis have become available in recent years. However, uncertainty exists regarding their long-term use and effectiveness. Bisphosphonate treatment, unlike ho...A number of effective therapies for the treatment of osteoporosis have become available in recent years. However, uncertainty exists regarding their long-term use and effectiveness. Bisphosphonate treatment, unlike hormone replacement, denosumab or teriparatide, is associated with benefits extended even after treatment discontinuation. The extended benefits are most apparent for alendronate （ALN） and zoledronate （ZOL）. A drug holiday might be considered in patients compliant with treatment, and who have had a response fractures the decision to consider a drug holiday should treatment. at low-moderate risk and who have been fully to treatment. In patients at low-moderate risk of be balanced also with the safety profile of each展开更多
目的探究尤瑞克林不同用药时长对急性缺血性脑卒中患者疗效和安全性的影响。方法本研究为RESK研究的亚组分析。从2015年8月到2020年6月共纳入65个中心的990例脑卒中患者,根据尤瑞克林用药时间长短分为短时用药组(用药8 d,n=185)和长时...目的探究尤瑞克林不同用药时长对急性缺血性脑卒中患者疗效和安全性的影响。方法本研究为RESK研究的亚组分析。从2015年8月到2020年6月共纳入65个中心的990例脑卒中患者,根据尤瑞克林用药时间长短分为短时用药组(用药8 d,n=185)和长时用药组(用药15 d和21 d,n=805)。分析患者90 d改良Rankin量表(mRS)评分为0分、0~1分和0~2分的患者比例,22 d美国国立卫生研究院卒中量表(NIHSS)评分较基线的变化,90 d Barthel指数≥95分患者比例和不良事件发生率。采用χ2检验、单因素和多因素Logistic回归分析等进行组间比较。结果多因素回归分析结果显示,短时用药组和长时用药组90 d mRS评分0~2分的患者比例[74.1%(137/185)比75.0%(604/805);OR=1.047,95%CI 0.676~1.620,P=0.838]和22 d NIHSS评分较基线的变化[(4.60±2.00)分比(4.26±2.80)分;OR=-0.390,95%CI-1.125~0.344,P=0.297],差异均无统计学意义;90 d mRS评分0~1分的患者比例[48.1%(89/185)比59.1%(476/805);OR=0.674,95%CI 0.463~0.983,P=0.041]和90 d Barthel指数≥95分患者比例[43.6%(79/181)比55.1%(442/802);OR=0.614,95%CI 0.420~0.897,P=0.012],在短时用药组均显著低于长时用药组。两组不良事件的发生率差异无统计学意义。结论对于急性缺血性脑卒中患者,尤瑞克林连续用药8 d即可改善患者近期(22 d NIHSS评分)和远期疗效(90 d mRS评分0~2分),且安全耐受。在条件允许的情况下,增加尤瑞克林用药时长可显著提高患者远期无残疾率(90 d mRS评分0~1分)和生活质量(90 d Barthel指数),且不增加不良事件风险。展开更多
BACKGROUND Acute cholangitis(AC)constitutes an infection with increased mortality rates in the past.Due to new diagnostic tools and therapeutic methods,the mortality of AC has been significantly reduced nowadays.The i...BACKGROUND Acute cholangitis(AC)constitutes an infection with increased mortality rates in the past.Due to new diagnostic tools and therapeutic methods,the mortality of AC has been significantly reduced nowadays.The initial antibiotic treatment of AC has been oriented to the most common pathogens connected to this infection.However,the optimal duration of the antibiotic treatment of AC is still debatable.AIM To investigate if shorter-course antibiotic treatments could be similarly effective to long-course treatments in adults with AC.METHODS This study constitutes a systematic review and meta-analysis of the existing literature concerning the duration of antibiotic therapy of AC and an assessment of the quality of the evidence.The study was conducted in accordance with the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analyses.Fifteen studies were included in the systematic review,and eight were eligible for meta-analysis.Due to heterogeneous duration cutoffs,three study-analysis groups were formed,with a cutoff of 2-3,6-7,and 14 d.RESULTS A total of 2763 patients were included in the systematic review,and 1313 were accounted for the meta-analysis.The mean age was 73.66±14.67 years,and the male and female ratio was 1:08.No significant differences were observed in the mortality rates of antibiotic treatment of 2-3 d,compared to longer treatments(odds ratio=0.78,95% confidence interval:0.23-2.67,I2=9%)and the recurrence rates and hospitalization length were also not different in all study groups.CONCLUSION Short-and long-course antibiotic treatments may be similarly effective concerning the mortality and recurrence rates of AC.Safe conclusions cannot be extracted concerning the hospitalization duration.展开更多
文摘A number of effective therapies for the treatment of osteoporosis have become available in recent years. However, uncertainty exists regarding their long-term use and effectiveness. Bisphosphonate treatment, unlike hormone replacement, denosumab or teriparatide, is associated with benefits extended even after treatment discontinuation. The extended benefits are most apparent for alendronate （ALN） and zoledronate （ZOL）. A drug holiday might be considered in patients compliant with treatment, and who have had a response fractures the decision to consider a drug holiday should treatment. at low-moderate risk and who have been fully to treatment. In patients at low-moderate risk of be balanced also with the safety profile of each
文摘目的探究尤瑞克林不同用药时长对急性缺血性脑卒中患者疗效和安全性的影响。方法本研究为RESK研究的亚组分析。从2015年8月到2020年6月共纳入65个中心的990例脑卒中患者,根据尤瑞克林用药时间长短分为短时用药组(用药8 d,n=185)和长时用药组(用药15 d和21 d,n=805)。分析患者90 d改良Rankin量表(mRS)评分为0分、0~1分和0~2分的患者比例,22 d美国国立卫生研究院卒中量表(NIHSS)评分较基线的变化,90 d Barthel指数≥95分患者比例和不良事件发生率。采用χ2检验、单因素和多因素Logistic回归分析等进行组间比较。结果多因素回归分析结果显示,短时用药组和长时用药组90 d mRS评分0~2分的患者比例[74.1%(137/185)比75.0%(604/805);OR=1.047,95%CI 0.676~1.620,P=0.838]和22 d NIHSS评分较基线的变化[(4.60±2.00)分比(4.26±2.80)分;OR=-0.390,95%CI-1.125~0.344,P=0.297],差异均无统计学意义;90 d mRS评分0~1分的患者比例[48.1%(89/185)比59.1%(476/805);OR=0.674,95%CI 0.463~0.983,P=0.041]和90 d Barthel指数≥95分患者比例[43.6%(79/181)比55.1%(442/802);OR=0.614,95%CI 0.420~0.897,P=0.012],在短时用药组均显著低于长时用药组。两组不良事件的发生率差异无统计学意义。结论对于急性缺血性脑卒中患者,尤瑞克林连续用药8 d即可改善患者近期(22 d NIHSS评分)和远期疗效(90 d mRS评分0~2分),且安全耐受。在条件允许的情况下,增加尤瑞克林用药时长可显著提高患者远期无残疾率(90 d mRS评分0~1分)和生活质量(90 d Barthel指数),且不增加不良事件风险。
文摘BACKGROUND Acute cholangitis(AC)constitutes an infection with increased mortality rates in the past.Due to new diagnostic tools and therapeutic methods,the mortality of AC has been significantly reduced nowadays.The initial antibiotic treatment of AC has been oriented to the most common pathogens connected to this infection.However,the optimal duration of the antibiotic treatment of AC is still debatable.AIM To investigate if shorter-course antibiotic treatments could be similarly effective to long-course treatments in adults with AC.METHODS This study constitutes a systematic review and meta-analysis of the existing literature concerning the duration of antibiotic therapy of AC and an assessment of the quality of the evidence.The study was conducted in accordance with the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analyses.Fifteen studies were included in the systematic review,and eight were eligible for meta-analysis.Due to heterogeneous duration cutoffs,three study-analysis groups were formed,with a cutoff of 2-3,6-7,and 14 d.RESULTS A total of 2763 patients were included in the systematic review,and 1313 were accounted for the meta-analysis.The mean age was 73.66±14.67 years,and the male and female ratio was 1:08.No significant differences were observed in the mortality rates of antibiotic treatment of 2-3 d,compared to longer treatments(odds ratio=0.78,95% confidence interval:0.23-2.67,I2=9%)and the recurrence rates and hospitalization length were also not different in all study groups.CONCLUSION Short-and long-course antibiotic treatments may be similarly effective concerning the mortality and recurrence rates of AC.Safe conclusions cannot be extracted concerning the hospitalization duration.
